Global Biosimilar Market Growth (Status and Outlook) 2023-2029

Global Biosimilar Market Growth (Status and Outlook) 2023-2029

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.
In this report is a biologic defined as proteins, peptides, hormones or antibody’s drugs production by bio-engineered technology, but does not include a vaccine.
LPI (LP Information)' newest research report, the “Biosimilar Industry Forecast” looks at past sales and reviews total world Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar sales for 2023 through 2029. With Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar.
The global Biosimilar market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
China’s core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.
In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer，with a share about 50%.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Segmentation by application
Cancer
Immunological Diseases
Diabetes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.